T1	intervention 31 45	platinum salts
T2	eligibility 661 795	Patients with operable breast cancer and immunophenotypically defined basal-like disease (ER-/PR-/HER2- and cytokeratin 5/6+ or EGFR+)
T3	outcome-Measure 1083 1119	pathological complete response (pCR)
T6	intervention 941 953	D (docetaxel
T9	total-participants 1175 1186	Ninety-four
T11	iv-bin-abs 1269 1271	16
T12	iv-bin-percent 1282 1286	35 %
T13	cv-bin-abs 1302 1304	14
T14	cv-bin-percent 1315 1319	30 %
T15	outcome 1351 1379	pCR in the breast and axilla
T10	outcome 1234 1256	pCR rate in the breast
T16	iv-bin-percent 1392 1396	30 %
T17	outcome 1427 1457	overall clinical response rate
T18	iv-bin-percent 1462 1466	70 %
T19	cv-bin-percent 1503 1507	77 %
T20	outcome 1543 1561	Grade 3/4 toxicity
T4	intervention 978 982	EC-D
T5	control 1048 1054	EC-DCb
